September 17, 2021 by archyde
|The Vaccine and Biologics Advisory Committee (VRBPAC), an FDA advisory body, held a meeting on the 17th (local time) and presented various data ahead of a vote on whether to recommend the FDA to approve the third dose of Pfizer-BioNtech’s COVID-19 vaccine. They are receiving reports and answering questions. © News 1|
The U.S. Food and Drug Administration (FDA) advisory panel holds a meeting on the 17th (local time) to discuss whether to give all Americans a booster shot of the COVID-19 vaccine.
The advisory group’s decision is an important step in the FDA’s final decision-making process and is drawing attention as it can influence booster-shot policy decisions around the world.
The Vaccines and Biologics Advisory Committee (VRBPAC), an FDA advisory body, will hold a meeting today and vote on whether to recommend to the FDA to approve the third dose of Pfizer-BioNtech’s COVID-19 vaccine.
Pfizer is requiring BoosterShot approval for people at least 16 years of age who have been vaccinated six months ago. Pfizer has submitted data to the FDA showing that antibodies in a clinical trial of 300 fully vaccinated people increased more than five-fold after boostershot vaccination.
Earlier, U.S. President Joe Biden urged the American people to take a booster shot on the 18th of last month, and the U.S. health authorities provided the FDA and the Centers for Disease Control and Prevention (CDC) approval to vaccinate Pfizer and Moderna eight months after completing vaccinations. It has been announced that booster shot vaccinations will be available from the week starting on the 20th. However, for reasons such as reviewing data, so far, only Pfizer vaccines are available for booster shots.
Currently, the advisory committee receives presentations on various research results from the FDA, CDC, and Pfizer through videoconference and continues to answer questions.
The advisory committee will also be briefed by Israeli health authorities. Israel has announced that it has significantly lowered the severity of COVID-19 through booster shots.
The committee’s key questions will be how quickly the vaccine loses effectiveness, how long the booster shot’s effectiveness lasts, and whether it’s safe and reduces transmission, the Washington Post said.
The conclusion of the meeting could serve as an opportunity to end the scientific and political debate over booster shot inoculation in recent weeks.
Some advisors have expressed a negative stance on the approval of the booster shot for the general public, saying that just two vaccinations are still effective in preventing serious patients and hospitalizations. Some also expressed the position that instead of booster shots, the vaccine should be provided to countries that are not yet vaccinated.
However, Anthony Fauci, director of the National Institute of Allergy, who oversees the White House’s COVID-19 response policy, is actively supporting the booster shot. Fauci said in an interview with The WP on the 16th that Israeli data suggest that booster shots could help stop the spread of COVID-19 and help contain the pandemic.
Experts predict that the advisory committee can choose one of several ways to support or reject the booster shot, or to recommend a small group over the age of 60 or 65. The advisory committee’s recommendations are not binding, but the FDA often follows them, the WP said.
[email protected]PUT 1xbet